Accelerating new cancer medicines in partnership with CBmed
Boehringer Ingelheim and CBmed join forces to translate novel cancer therapy approaches faster into new medicines for patients
Search
CHMP recommends new treatment for chronic kidney disease
The CHMP of EMA has granted a positive opinion recommending empagliflozin for the treatment of adults with chronic kidney disease
License deal with A*STAR to develop cancer antibodies
License deal with A*STAR to develop cancer antibodies
Behavioral science to improve cattle well-being
Boehringer Ingelheim kicks off a project based on behavioral science to improve cattle well-being
Partnership with IBM to accelerate new antibody therapies
Boehringer Ingelheim collaborates with IBM to advance generative AI and foundation models for therapeutic antibody development
survodutide top-line results MASH fibrosis
Survodutide Phase II trial shows 83% of adults treated achieved groundbreaking results in liver disease due to MASH, with significant improvements in fibrosis
Trends & Insights
Trends & Insights
Inauguration of new integrated Asian Veterinary R&D Center in China
Boehringer Ingelheim confirms its commitment to growth in China with the investment of 19 million euros in its new integrated Asian Veterinary Research & Development Center
Aservo EquiHaler wins Pharmapack Award 2021
Boehringer Ingelheim’s Aservo® EquiHaler® is recognized in the 2021 Pharmapack Awards
New cancer therapeutics collaboration with 3T Bio
Boehringer Ingelheim and 3T Biosciences collaborate to discover and develop next-generation cancer therapies to address high unmet patient needs
Boehringer Ingelheim collaborates with Circle Pharma
Boehringer Ingelheim collaborates with Circle Pharma to develop a first-in-class cyclin RxL inhibitor that can halt the growth of cancer cells
Brand of the Year Frontline pet parasiticides
FRONTLINE® Wins Brand of the Year Award for the Third Time in a row
Collaboration with Mary Tyler Moore Vision Initiative
Boehringer Ingelheim joins forces with Mary Tyler Moore Vision Initiative to combat vision loss from diabetes
Animal Health partnering interests
Animal Health partnering interests
Positivity... just a paw away
Data released by Boehringer Ingelheim shows the 96% of dog owners and 91% of cat owners claim their pet has a positive impact on their daily lives.
Three challenges shape future antiparasitic treatment
The three key challenges that will shape the future of antiparasitic treatment
Overcoming heartworm disease for homeless pets
Heartworm-free pets soar to new lives. Together with our Greater Good Charity partners, our colleagues helped bring shelter dogs to forever homes.
International Women's Day
We celebrate International Women’s Day with this year’s UN Women motto being “Gender Equality Today for a Sustainable Tomorrow”
The GPP Forum
The generalized pustular psoriasis (GPP) Forum - a multistakeholder event collaborating for a new vision for people living with GPP
Introducing CIAS
Schizophrenia affects 1 in 100, yet the condition can be misunderstood due to some symptoms being overlooked, such as cognitive impairment
Generalized pustular psoriasis: Unmet needs
Dr Clerisme-Beaty and Dr Strober MD, PhD discuss the impact of living with GPP including unseen challenges and future management.
Improving lives by providing better access to treatments
Our ‘Access to Healthcare’ initiative aims to extend support to underserved communities affected by Non-Communicable Diseases
Registration Microbial Expert Workshop
Connect with our microbial specialists in Boston
Expectations towards our business partners
We utilize an extensive network of international suppliers for procuring raw materials, intermediates, packaging materials, technical components and services to deliver our innovative medications worldwide.
Patient Organizations
Boehringer Ingelheim’s core principles and vision guide our work with patient organisations.